Tower Research Capital (TRC)’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $51.4K | Buy |
12,849
+242
| +2% | +$968 | ﹤0.01% | 2950 |
|
|
2025
Q1 | $11.5K | Buy |
12,607
+8,884
| +239% | +$8.08K | ﹤0.01% | 3534 |
|
|
2024
Q4 | $10.3K | Buy |
3,723
+1,921
| +107% | +$5.32K | ﹤0.01% | 3813 |
|
|
2024
Q3 | $9.42K | Sell |
1,802
-4,717
| -72% | -$24.7K | ﹤0.01% | 3868 |
|
|
2024
Q2 | $29.1K | Buy |
6,519
+6,121
| +1,538% | +$27.3K | ﹤0.01% | 3506 |
|
|
2024
Q1 | $3.05K | Sell |
398
-3,494
| -90% | -$26.8K | ﹤0.01% | 4938 |
|
|
2023
Q4 | $16.6K | Sell |
3,892
-4,440
| -53% | -$18.9K | ﹤0.01% | 3775 |
|
|
2023
Q3 | $35K | Buy |
8,332
+4,777
| +134% | +$20.1K | ﹤0.01% | 2881 |
|
|
2023
Q2 | $19.8K | Sell |
3,555
-10,538
| -75% | -$58.7K | ﹤0.01% | 3374 |
|
|
2023
Q1 | $81K | Buy |
14,093
+10,495
| +292% | +$60.3K | ﹤0.01% | 2060 |
|
|
2022
Q4 | $4K | Buy |
+3,598
| New | +$4K | ﹤0.01% | 5018 |
|
|
2022
Q2 | – | Sell |
-2,430
| Closed | -$10K | – | 6282 |
|
|
2022
Q1 | $10K | Buy |
2,430
+1,028
| +73% | +$4.23K | ﹤0.01% | 4315 |
|
|
2021
Q4 | $10K | Buy |
1,402
+597
| +74% | +$4.26K | ﹤0.01% | 4571 |
|
|
2021
Q3 | $9K | Sell |
805
-374
| -32% | -$4.18K | ﹤0.01% | 4443 |
|
|
2021
Q2 | $20K | Buy |
1,179
+20
| +2% | +$339 | ﹤0.01% | 3886 |
|
|
2021
Q1 | $23K | Sell |
1,159
-241
| -17% | -$4.78K | ﹤0.01% | 3777 |
|
|
2020
Q4 | $29K | Buy |
1,400
+141
| +11% | +$2.92K | ﹤0.01% | 3594 |
|
|
2020
Q3 | $33K | Buy |
+1,259
| New | +$33K | ﹤0.01% | 3694 |
|